Prognostic value of normal technetium-99m-sestamibi cardiac imaging.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 8151374.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The purpose of this study was to describe the clinical outcome of patients with a normal 99mTc-sestamibi cardiac imaging study. One-day gated rest-stress planar dipyridamole (n = 112) and symptom-limited exercise (n = 122) 99mTc-sestamibi protocols were used. All patients (n = 234, mean age 55 +/- 12 yr, 127 males and 107 females) had normal perfusion and wall motion on qualitative analysis. Patients were followed for 6-16 mo (mean 10 +/- 2 mo). Cardiac events were defined as cardiac death or nonfatal myocardial infarction. ST-segment depression or chest pain occurred in 8 (7%) and 29 (26%) patients in the dipyridamole group, respectively, and 20 (16%) and 28 (22%) patients in the exercise group. Cardiac events occurred in only one patient. The annualized event rate was 0.5% per year. In addition, only two patients underwent coronary revascularization during the follow-up period. Our data confirm the benign outcome of patients with normal 99mTc-sestamibi cardiac imaging, at least over an intermediate follow-up period.
Medical subject headings
- Coronary Disease
- Heart
- Technetium Tc 99m Sestamibi